NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process
15 août 2024 16h03 HE
|
NurExone Biologic Inc
NurExone’s reliable production from diverse biological sources allows NurExone to optimize exosome production with consistency and efficiency
NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study
09 août 2024 16h04 HE
|
NurExone Biologic Inc
NurExone announces promising new data for its ExoPTEN nanodrug, highlighting progress towards commercial-grade manufacturing
NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer
01 août 2024 16h04 HE
|
NurExone Biologic Inc
NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer
NurExone Announces Further Expansion of ExoPTEN Patent Coverage
29 juil. 2024 16h04 HE
|
NurExone Biologic Inc
NurExone Announces Further Expansion of ExoPTEN Patent Coverage in Israel
Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma
17 juil. 2024 16h14 HE
|
NurExone Biologic Inc
TORONTO and HAIFA, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company,...
Updates from NurExone: Growth Conference Presentation and Website Relaunch
05 juil. 2024 08h43 HE
|
NurExone Biologic Inc
TORONTO and HAIFA, Israel, July 05, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company,...
NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market
28 juin 2024 16h04 HE
|
NurExone Biologic Inc
Prestigious Eye Institute Exploring New Indication for NurExone’s ExoPTEN
On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
21 juin 2024 16h04 HE
|
NurExone Biologic Inc
TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company,...
NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application
11 juin 2024 08h44 HE
|
NurExone Biologic Inc
NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application
NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders
04 juin 2024 16h40 HE
|
NurExone Biologic Inc
NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders